Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
Go back to Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records| (NASDAQ: BBIO) | Delayed: 67.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.74 | 52 Week High | $ | |||
| Open | $67.74 | 52 Week Low | $ | |||
| Day High | $67.74 | P/E | N/A | |||
| Day Low | $67.74 | EPS | $ | |||
| Volume | 8 | |||||



